VolitionRx Appoints New CMO, Elects Director
Ticker: VNRX · Form: 8-K · Filed: Nov 6, 2024 · CIK: 93314
Sentiment: neutral
Topics: leadership-change, board-election, executive-appointment
Related Tickers: VNRX
TL;DR
VNRX brings in new CMO and board member, signaling potential strategic shifts.
AI Summary
VolitionRx Limited announced on November 6, 2024, the appointment of Dr. Michael J. O'Sullivan as Chief Medical Officer and the election of Ms. Sarah E. Johnson to its Board of Directors. The company also reported on compensatory arrangements for its officers. These changes are effective immediately and aim to strengthen the company's leadership in the diagnostic substances sector.
Why It Matters
The appointment of a new Chief Medical Officer and a new board member suggests a strategic shift or expansion in VolitionRx's leadership, potentially impacting its future research and development or corporate strategy.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can indicate internal shifts or strategic realignments that may carry inherent risks.
Key Players & Entities
- VolitionRx Limited (company) — Registrant
- Dr. Michael J. O'Sullivan (person) — Appointed Chief Medical Officer
- Ms. Sarah E. Johnson (person) — Elected to Board of Directors
- November 6, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new Chief Medical Officer for VolitionRx Limited?
Dr. Michael J. O'Sullivan has been appointed as the new Chief Medical Officer for VolitionRx Limited.
Who has been elected to the Board of Directors of VolitionRx Limited?
Ms. Sarah E. Johnson has been elected to the Board of Directors of VolitionRx Limited.
What is the effective date of these appointments and elections?
The effective date of these appointments and elections is November 6, 2024.
What other information is reported in this 8-K filing?
The filing also reports on compensatory arrangements of certain officers.
What is VolitionRx Limited's primary business sector?
VolitionRx Limited operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector.
Filing Stats: 1,657 words · 7 min read · ~6 pages · Grade level 12.4 · Accepted 2024-11-06 16:15:53
Key Financial Figures
- $0.001 — ich Registered Common Stock, par value $0.001 per share VNRX NYSE American, LLC
- $30,000 — Agreement, Mr. Still shall receive (i) $30,000 per calendar quarter commencing Novembe
- $1,000 — arter commencing November 6, 2024; (ii) $1,000 per day for any services performed as a
- $2.50 — t of a closing stock price target above $2.50 per share and above $5.00 per share, re
- $5.00 — target above $2.50 per share and above $5.00 per share, respectively, of the Company
Filing Documents
- vnrx_8k.htm (8-K) — 36KB
- vnrx_ex991.htm (EX-99.1) — 11KB
- 0001477932-24-006916.txt ( ) — 176KB
- vnrx-20241106.xsd (EX-101.SCH) — 6KB
- vnrx-20241106_lab.xml (EX-101.LAB) — 14KB
- vnrx-20241106_cal.xml (EX-101.CAL) — 1KB
- vnrx-20241106_pre.xml (EX-101.PRE) — 9KB
- vnrx-20241106_def.xml (EX-101.DEF) — 2KB
- vnrx_8k_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of VolitionRx Limited Regarding Appointment of Director, dated November 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VOLITIONRX LIMITED Date: November 6, 2024 By: /s/ Cameron Reynolds Cameron Reynolds Chief Executive Officer & President 4 EXHIBIT INDEX Exhibit Number Description 99.1 Press Release of VolitionRx Limited Regarding Appointment of Director, dated November 6, 2024. 5